570 related articles for article (PubMed ID: 25583838)
1. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
[TBL] [Abstract][Full Text] [Related]
2. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
Mancardi GL; Sormani MP; Gualandi F; Saiz A; Carreras E; Merelli E; Donelli A; Lugaresi A; Di Bartolomeo P; Rottoli MR; Rambaldi A; Amato MP; Massacesi L; Di Gioia M; Vuolo L; Currò D; Roccatagliata L; Filippi M; Aguglia U; Iacopino P; Farge D; Saccardi R; ;
Neurology; 2015 Mar; 84(10):981-8. PubMed ID: 25672923
[TBL] [Abstract][Full Text] [Related]
3. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
[TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience.
Mancardi GL; Sormani MP; Di Gioia M; Vuolo L; Gualandi F; Amato MP; Capello E; Currò D; Uccelli A; Bertolotto A; Gasperini C; Lugaresi A; Merelli E; Meucci G; Motti L; Tola MR; Scarpini E; Repice AM; Massacesi L; Saccardi R;
Mult Scler; 2012 Jun; 18(6):835-42. PubMed ID: 22127896
[TBL] [Abstract][Full Text] [Related]
5. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
[TBL] [Abstract][Full Text] [Related]
6. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
[TBL] [Abstract][Full Text] [Related]
7. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.
Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS
Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
[TBL] [Abstract][Full Text] [Related]
9. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
[TBL] [Abstract][Full Text] [Related]
11. Autologous hematopoietic stem cell transplantation significantly alters circulating ceramides in peripheral blood of relapsing-remitting multiple sclerosis patients.
Vaivade A; Wiberg A; Khoonsari PE; Carlsson H; Herman S; Al-Grety A; Freyhult E; Olsson-Strömberg U; Burman J; Kultima K
Lipids Health Dis; 2023 Jul; 22(1):97. PubMed ID: 37420217
[TBL] [Abstract][Full Text] [Related]
12. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP; Muraro PA; Saccardi R; Mancardi G
Mult Scler; 2017 Feb; 23(2):201-204. PubMed ID: 27207454
[TBL] [Abstract][Full Text] [Related]
13. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
[TBL] [Abstract][Full Text] [Related]
14. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
[TBL] [Abstract][Full Text] [Related]
15. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
[TBL] [Abstract][Full Text] [Related]
16. Autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis - whom, when and how.
Szczechowski L; Śmiłowski M; Helbig G; Krawczyk-Kuliś M; Kyrcz-Krzemień S
Int J Neurosci; 2016 Oct; 126(10):867-71. PubMed ID: 26577419
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of autologous hematopoietic stem-cell transplantation following natalizumab discontinuation in aggressive multiple sclerosis.
Mariottini A; Innocenti C; Forci B; Magnani E; Mechi C; Barilaro A; Nistri R; Fani A; Saccardi R; Massacesi L; Repice AM
Eur J Neurol; 2019 Apr; 26(4):624-630. PubMed ID: 30414315
[TBL] [Abstract][Full Text] [Related]
18. Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.
Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kartashov AV; Kurbatova KA; Gorodokin GI; Novik AA
Exp Hematol; 2012 Nov; 40(11):892-8. PubMed ID: 22771495
[TBL] [Abstract][Full Text] [Related]
19. Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two cases.
Portaccio E; Amato MP; Siracusa G; Pagliai F; Sorbi S; Guidi S; Bosi A; Saccardi R
Mult Scler; 2007 Jun; 13(5):676-8. PubMed ID: 17548451
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation in multiple sclerosis.
Rogojan C; Frederiksen JL
Acta Neurol Scand; 2009 Dec; 120(6):371-82. PubMed ID: 19785643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]